Retinopathy Of Prematurity - Pipeline Review, H1 2015

Description: Retinopathy Of Prematurity - Pipeline Review, H1 2015

Summary

This, ‘Retinopathy Of Prematurity - Pipeline Review, H1 2015’, provides an overview of the Retinopathy Of Prematurity's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Retinopathy Of Prematurity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinopathy Of Prematurity and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Retinopathy Of Prematurity
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Retinopathy Of Prematurity and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Retinopathy Of Prematurity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Retinopathy Of Prematurity pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Retinopathy Of Prematurity
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Retinopathy Of Prematurity pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Retinopathy Of Prematurity Overview
Therapeutics Development
Pipeline Products for Retinopathy Of Prematurity - Overview
Pipeline Products for Retinopathy Of Prematurity - Comparative Analysis
Retinopathy Of Prematurity - Therapeutics under Development by Companies
Retinopathy Of Prematurity - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Retinopathy Of Prematurity - Products under Development by Companies
Retinopathy Of Prematurity - Companies Involved in Therapeutics Development
Acucela Inc.
Biomar Microbial Technologies
EyeGene, Inc.
F. Hoffmann-La Roche Ltd.
Gene Signal International SA
Insmed Incorporated
Retinopathy Of Prematurity - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
aganirsen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EG-Mirotin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
emixustat hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IB-09A0133 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mecasermin rinfabate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ranibizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Retinopathy of Prematurity - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Retinopathy Of Prematurity - Recent Pipeline Updates
Retinopathy Of Prematurity - Product Development Milestones
Featured News & Press Releases
Apr 29, 2008: Acucela Presents Preclinical Data From Retinopathy Study Demonstrating Improvement In Retinal Abnormalities
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Retinopathy Of Prematurity, H1 2015
Number of Products under Development for Retinopathy Of Prematurity - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Retinopathy Of Prematurity - Pipeline by Acucela Inc., H1 2015
Retinopathy Of Prematurity - Pipeline by Biomar Microbial Technologies, H1 2015
Retinopathy Of Prematurity - Pipeline by EyeGene, Inc., H1 2015
Retinopathy Of Prematurity - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Retinopathy Of Prematurity - Pipeline by Gene Signal International SA, H1 2015
Retinopathy Of Prematurity - Pipeline by Insmed Incorporated, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Retinopathy Of Prematurity Therapeutics - Recent Pipeline Updates, H1 2015

List of Figures
Number of Products under Development for Retinopathy Of Prematurity, H1 2015
Number of Products under Development for Retinopathy Of Prematurity - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3112134/
Order by Fax - using the form below
Order by Post - print the order form below and send to Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Retinopathy Of Prematurity - Pipeline Review, H1 2015
Web Address: http://www.researchandmarkets.com/reports/3112134/
Office Code: SCD2KDC9

Product Formats
Please select the product formats and quantity you require:

Quantity
Electronic (PDF) - Single User: USD 2000
Electronic (PDF) - Site License: USD 4000
Electronic (PDF) - Enterprisewide: USD 6000

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  Mr  [ ]  Mrs  [ ]  Dr  [ ]  Miss  [ ]  Ms  [ ]  Prof  [ ]
First Name: ___________________________  Last Name: ___________________________
Email Address: * ________________________________
Job Title: __________________________________
Organisation: _____________________________
Address: __________________________________
City: _____________________________________
Postal / Zip Code: __________________________
Country: __________________________________
Phone Number: ____________________________
Fax Number: ______________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp